Alkermes to Report Second Quarter Financial Results on July 29, 2025
Alkermes (Nasdaq: ALKS), a global biopharmaceutical company focused on neuroscience, has scheduled its second quarter 2025 financial results conference call and webcast for July 29, 2025, at 8:00 a.m. ET.
The company specializes in developing treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Their pipeline includes clinical and preclinical candidates for neurological disorders such as narcolepsy and idiopathic hypersomnia. Alkermes maintains operations across Ireland, Massachusetts, and Ohio.
Alkermes (Nasdaq: ALKS), un'azienda biofarmaceutica globale specializzata in neuroscienze, ha programmato la conferenza telefonica e la webcast per la presentazione dei risultati finanziari del secondo trimestre 2025 per il 29 luglio 2025 alle 8:00 ET.
L'azienda si dedica allo sviluppo di terapie per la dipendenza da alcol, dipendenza da oppioidi, schizofrenia e disturbo bipolare di tipo I. Il loro portafoglio comprende candidati clinici e preclinici per disturbi neurologici come la narcolessia e l'ipersonnia idiopatica. Alkermes opera in Irlanda, Massachusetts e Ohio.
Alkermes (Nasdaq: ALKS), una compa帽铆a biofarmac茅utica global enfocada en neurociencia, ha programado su llamada de conferencia y webcast para los resultados financieros del segundo trimestre de 2025 para el 29 de julio de 2025 a las 8:00 a.m. ET.
La empresa se especializa en desarrollar tratamientos para la dependencia del alcohol, dependencia de opioides, esquizofrenia y trastorno bipolar I. Su cartera incluye candidatos cl铆nicos y precl铆nicos para trastornos neurol贸gicos como la narcolepsia y la hipersomnia idiop谩tica. Alkermes mantiene operaciones en Irlanda, Massachusetts y Ohio.
Alkermes (雮橃姢雼�: ALKS)電� 鞁犼步瓿柬暀鞐� 欷戩爯鞚� 霊� 旮�搿滊矊 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 2攵勱赴 鞛 鞁れ爜 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 2025雲� 7鞗� 29鞚� 鞓れ爠 8鞁�(霃欕秬鞁滉皠)鞐� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟.
鞚� 須岇偓電� 鞎岇綌鞓� 鞚橃〈歃�, 鞓ろ敿鞓れ澊霌� 鞚橃〈歃�, 鞝曥嫚攵勳棿歃�, 鞏戧饭靹� 鞛レ暊 I順� 旃橂鞝� 臧滊皽鞐� 韸鬼檾霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 旮半┐歃濌臣 韸闺皽靹� 瓿茧嫟靾橂┐歃� 臧欖潃 鞁犼步頃欖爜 歆堩櫂鞐� 雽�頃� 鞛勳儊 氚� 鞝勳瀯靸� 頉勲炒氍检霃� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Alkermes電� 鞎勳澕霝滊摐, 毵れ偓於旍劯旄�, 鞓ろ晿鞚挫槫鞐愳劀 鞖挫榿霅橁碃 鞛堨姷雼堧嫟.
Alkermes (Nasdaq : ALKS), une entreprise biopharmaceutique mondiale sp茅cialis茅e en neurosciences, a programm茅 sa conf茅rence t茅l茅phonique et webcast pour les r茅sultats financiers du deuxi猫me trimestre 2025 le 29 juillet 2025 脿 8h00 ET.
La soci茅t茅 se concentre sur le d茅veloppement de traitements pour la d茅pendance 脿 l'alcool, la d茅pendance aux opio茂des, la schizophr茅nie et le trouble bipolaire de type I. Son portefeuille comprend des candidats cliniques et pr茅cliniques pour des troubles neurologiques tels que la narcolepsie et l'hypersomnie idiopathique. Alkermes op猫re en Irlande, dans le Massachusetts et dans l'Ohio.
Alkermes (Nasdaq: ALKS), ein globales biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften, hat seine Telefonkonferenz und Webcast zur Ver枚ffentlichung der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r den 29. Juli 2025 um 8:00 Uhr ET angesetzt.
Das Unternehmen spezialisiert sich auf die Entwicklung von Behandlungen f眉r Alkoholabh盲ngigkeit, Opioidabh盲ngigkeit, Schizophrenie und bipolare St枚rung Typ I. Die Pipeline umfasst klinische und pr盲klinische Kandidaten f眉r neurologische Erkrankungen wie Narkolepsie und idiopathische Hypersomnie. Alkermes ist in Irland, Massachusetts und Ohio t盲tig.
- None.
- None.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at . The conference call may be accessed by dialing +1 877 407 2988 for
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:
SOURCE Alkermes plc
FAQ
When will Alkermes (ALKS) report Q2 2025 earnings?
How can investors access Alkermes' Q2 2025 earnings call?
What therapeutic areas does Alkermes (ALKS) focus on?
Where are Alkermes' main operations located?
